SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
Date of Report: September 21, 1999
BIORA AB
SE-205 12 Malmo, Sweden
Telephone: (011) 46-40-32-13-33
Indicate by a check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
|X| Form 20-F |_| Form 40-F
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
|_| Yes |X| No
If "Yes" is marked, indicate below the file number assigned to
the registrant in connection with Rule 12g3-2(b):
Not applicable.
This Form 6-K consists of a press release issued by Biora AB on
September 21, 1999 relating to Biora's North American subsidiary, Biora,
Inc., winning the "1999 Swedish Trade Council North America Annual
Achievement Award."
PRESIDENT AND CEO INVESTOR RELATIONS U.S INVESTOR RELATIONS
TOMAS HAMMARGREN MIKAEL SJOBLOM ELISABETH LAVERS
+46 40 32 13 36 +46 40 32 13 65 +1 203 977 7797
BIORA WON "1999 SWEDISH TRADE COUNCIL
NORTH AMERICA ANNUAL ACHIEVEMENT AWARD"
Malmo, Sweden, September 10, 1999 - Biora AB (NASDAQ: BIORY, SSE: BIOR)
today announced that Biora, Inc. the North American subsidiary of the
Swedish biotech company Biora AB has won the "1999 Swedish Trade Council
North America Annual Achievement Award", which means that Biora, Inc. is
the Swedish subsidiary of the year on the North American market. The
Nominating Committee recommended Biora for this award for "Effective
Introduction of Innovative Medical Technology".
The Nominating Committee gave the following statement: "Biora's product
Emdogain - a major innovation in the treatment of periodontal disease - was
introduced to skeptical US periodontists in early 1997. Their successful
strategy has been to focus on clinical trials, education and the opinion
leaders of the periodontal profession. Already today, Biora has secured a
50% penetration rate in its target US market segment and is now on its way
to success in Canada and Mexico as well."
"This is of course a significant achievement as it recognizes our efforts
on the important American market" says Biora's CEO Tomas Hammargren. "It
also proves that small companies can succeed if they have a strong product
and a well-defined target group."
"The staff in our American subsidiary has done a fantastic job during the
past two years. Although the initial success in the U.S. market has been
excellent we have only scratched the surface in terms of the opportunity
for Biora on the North American market."
"Biora, Inc.'s success can be attributed to the efforts of our excellent
team who's common goal has been to develop and grow Biora in a professional
and effective manner", says Donna Janson, President of Biora, Inc. "We are
also most grateful to those customers who believed in Emdogain and Biora
from the very beginning and have helped us tremendously through their
continuos support. And of course we have been extremely fortunate to have
the trust and confidence of our Swedish parent company, whose support of
our efforts has enabled us to achieve our goals."
The 1999 Annual Achievement Award Ceremony is planned for October 25 at a
reception hosted by Ambassador Rolf Ekeus at the Ambassador's Residence in
Washington DC.
Biora develops, manufactures and sells products for the treatment of
periodontal disease and for use in oral surgery. Using its proprietary
technology and expertise, Biora aims to become a world leader in
biology-based products for specialized dental therapy. Biora's American
Depository Shares are listed on the Nasdaq National Market in the US and
Biora's ordinary shares are listed on the "O-list" of the Stockholm Stock
Exchange in Sweden.
This press release may contain certain forward-looking statements that
relate to future events or future business and financial performance. Such
statements can only be predictions and the actual events or results may
differ from those discussed. The Company cautions that these statements are
subject to important factors that could cause actual results to differ
materially from those expressed or implied in such forward looking
statements and are more fully discussed in periodic reports filed with
Securities and Exchange Commission.
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
BIORA AB
Dated: September 21, 1999 By: /s/ Anders Agering
______________________________
Anders Agering
Chief Financial Officer
